RATCHAPHRUEK HOSPITAL PUBLIC COMPANY LIMITEDSET: RPH🇹🇭 TH

Business Operation · 2025

Corporate Information

Company Name

RATCHAPHRUEK HOSPITAL PUBLIC COMPANY LIMITED

Telephone

0-4333-3555

Website

http://www.rph.co.th

Email

info@rph.co.th

Dividend Policy

Dividend Policy

The Company has a policy to pay dividends to shareholders at a rate of not less than 40% of the net profit based on the separate financial statements, after deduction of corporate income tax, statutory reserves, and other reserves (if any).

However, the actual dividend payment may vary depending on the Company’s operating results, financial position, liquidity, the need for working capital in business operations, future investment and business expansion plans, market conditions, and other relevant factors related to the Company’s operations and management, as deemed appropriate by the Board of Directors.

Historical Dividend Payments

This YearLast Year2 Years Ago3 Years Ago4 Years AgoMetricDescriptionRemark
0.340.320.340.520.74Net profit per share (Baht : Share)Net profit per share (baht : share)
0.280.290.30.350.3Dividend per share (Baht : Share)Dividend per share (baht : share)
1) The Board of Directors' Meeting No. 3/2025 resolved to approve the interim dividend payment from the operating results for the first 6 months (January 1 - June 30, 2025) of 2025 in the amount of THB 0.10 per share, which was paid on September 9, 2025. 2) The Board of Directors' Meeting No. 2/2026, held on February 14, 2026, resolved to propose to the Annual General Meeting of Shareholders to consider and approve the dividend payment from the operating results for the second 6 months (July 1 - December 31, 2025) of 2025 in the amount of THB 0.18 per share. Therefore, the Company will pay a cash dividend to shareholders from the operating results for 2025 in the amount of THB 0.28 per share. However, the dividend payment is still uncertain and must be approved by the Annual General Meeting of Shareholders in 2026.
00000Dividend stock ratio (Number of original shares: dividend shares)Ratio of stock dividend payment (existing share : stock dividend)
00000Dividend share value per share (Baht : Share)Value of stock dividend per share (baht : share)
0.280.290.30.350.3Total dividend payment value (Baht : Share)Total dividend payment (baht : share)
79.9390.3888.7966.7140.65Dividend payout ratio to net profit (%)Dividend payout ratio compared to net profit (%)

Major Shareholders

Major Shareholders

No.NameShares% Shares
27,210MR.TEERAWAT SRINAKARIN66,175,10012.12
27,211MR.VALLOP LAOPAIBOON26,212,0604.8
27,212MS.AUMPORN RUEANGPRASERTKUL22,000,0004.03
27,213MR.THANA SIRITHANACHAI18,644,0003.41
27,214RATCHAPHRUEK HOSPITAL PUBLIC COMPANY LIMITED15,593,0002.86
27,215MR. PISUTH VIRIYAMETTAKUL15,000,0002.75
27,216MS.RATCHANEE LAOPAIBOON10,476,6201.92
27,217MR.PATTANA LAOPAIBOON10,113,5701.85
27,218MRS.JIRAPORN SRINAKARIN10,020,0001.84
27,219MR. APICHART KHOBJAI9,693,1801.78
27,220MR.SUDHON SRIYAPANT8,800,8101.61
27,221MR.NUNTAWAT MANEEROD8,774,1101.61
27,222MR. WARARIT SIRITANACHAI7,490,0001.37
27,223MR. SRICHAI KRUSUN7,000,0001.28
27,224MR.SOMSAK TUNKPITAKSAKUL6,575,0001.2
27,225MR. BHOTONG PANGPHUTHIPONG5,892,6001.08
27,226MR. VINAI TANTIYASAWASDIKUL5,823,7601.07
27,227MR. ADISORN DEEPRASITTIPONG5,520,0001.01
27,228MR.WEERA KRUSUN5,000,0000.92
27,229MR. KANPANT SRIYAPANT4,620,4000.85
27,230MR. VORATHEP RANGCHAIKUL4,530,0000.83
27,231MR. BRIAN WIBULOUTAI4,506,6000.83
27,232MR.VICHAI SAENGTHONGKUL4,100,0000.75
27,233MR.TEERAWAT MANEEROD3,350,0000.61
27,234MR.LAKKANA LAOPAIBOON3,244,9000.59
27,235MRS.MALINEE LAOPAIBOON3,123,4800.57
27,236MRS. WILAI TONMITR3,100,5500.57
27,237Thai NVDR Company Limited3,072,7950.56
27,238MR. BOONSONG JENWECHPRASERT3,020,0700.55
27,239MR. WITTAYA LAOPAIBOON2,997,7400.55
27,240MR.WARONG LAOPAIBOON2,877,3200.53
27,241MR.BUNCHA TUNCHAWALIT2,785,0300.51

Remark

The latest information following the book closing date as of 27 August 2025.

Business Strategies Overview

Chairman's Message

Today’s healthcare industry is no longer measured merely by the number of beds or the size of hospital facilities. It is shaped by multiple challenges at once — an aging society, rising medical costs, increasing expectations for quality and responsiveness, rapid technological change, and economic uncertainty. These challenges require careful judgment, integrity in decision-making, and a strong sense of responsibility.

Ratchaphruek Hospital was founded by a group of physicians who firmly believed that medical care is not simply a service, but an act of caring for fellow human beings. This belief remains the foundation of our organization today. We have never defined success solely by financial results. Instead, we measure it by the trust of our patients, the quality of care we provide, and the peace of mind experienced by patients and their families.

As Chairman of the Board, I strongly believe that long-term sustainability begins with serious commitment to standards, straightforward management, and sincere accountability to all stakeholders. The Board therefore places great emphasis on good corporate governance, transparency, and effective oversight, ensuring that every decision is made with responsibility and the collective interest in mind.

Despite rapid changes in the economic environment and increasing competition, Ratchaphruek Hospital remains committed to continuously improving quality of care, patient safety, specialized medical services, and the practical use of innovation and digital technology. At the same time, we remain true to our core identity as a hospital that is accessible, compassionate, and closely connected to the communities we serve.

On behalf of the Board of Directors, I would like to express my sincere appreciation to our shareholders, patients, employees, business partners, and all stakeholders for their continued trust and support. The Board remains fully committed to fulfilling its duties with determination and integrity, guiding Ratchaphruek Hospital forward as a trusted healthcare institution and a sustainably growing organization for the long term.

(Mr.Sudhon Sriyapant)

Chairman of the Board

Vision

"We are determined to be the leading private hospital that provide international high-quality standard and

humanized care"

Objectives

1. The company's business operations will prioritize the quality and safety of patients and service recipients, emphasizing holistic patient care with a heart of humanity.

2. Aiming to be a Beyond Hospital for Khon Kaen residents and the public.

3. Creating quality service standards and focusing on individuals as the person centered care.

Goals

Ratchaphruek Hospital Public Company Limited operates its healthcare business with the belief that providing medical care is, at its core, caring for fellow human beings. The Company therefore strives to maintain a balanced approach between quality of care, patient safety, social responsibility, and sustainable organizational growth. Rather than focusing solely on profit maximization, the Company places emphasis on the value of human life, trust, compassion, and long-term relationships with all stakeholders.

The Company’s key objectives are as follows:

  1. To provide patient care with compassion and a human-centered approach

    To deliver medical services with empathy, care, and respect for human dignity, placing patient safety, quality of care, and patient experience at the center of all services.

  2. To continuously enhance the quality of care in line with international standards

    To develop healthcare systems, clinical processes, and patient safety standards to ensure reliable, effective, and high-quality medical services that inspire confidence among patients and their families.

  3. To promote equitable and appropriate access to healthcare services

    To expand service models and delivery channels that enable individuals and communities to access necessary healthcare services conveniently, promptly, and in a manner appropriate to their needs and circumstances.

  4. To strengthen medical expertise and human capital

    To support the continuous development of medical professionals and related personnel, alongside the advancement of specialized medical services and healthcare technologies, in order to respond to diverse and evolving healthcare needs.

  5. To manage the organization with responsibility, transparency, and good governance

    To conduct business in accordance with principles of good corporate governance, integrity, and regulatory compliance, thereby fostering confidence among shareholders, investors, and other stakeholders.

  6. To achieve sustainable growth while creating shared value for society and the environment

    To operate the business with due consideration of social, community, and environmental impacts, promote the efficient use of resources, and pursue balanced long-term growth, ensuring that the Hospital remains a trusted healthcare partner for society.

Business Strategies

Strategic Directions of the Company

1) Strengthening Brand Building and Positioning

The Company aims to strengthen its brand positioning as a private hospital that emphasizes high-quality medical care delivered with warmth and compassion. Key initiatives include:

  • Creating a patient-centered and welcoming medical experience

  • Expanding the capabilities and recognition of specialist and subspecialist physicians

  • Implementing marketing and brand communication activities to enhance brand awareness, credibility, and long-term trust

2) Maximizing the Utilization of Existing Hospital Assets

The Company focuses on enhancing the efficiency and effectiveness of its existing hospital resources by emphasizing:

  • The provision of high-quality healthcare and well-being services

  • The expansion and development of specialized medical centers to strengthen service capabilities and meet patient demand

3) Expanding the Patient Base

The Company seeks to broaden its patient base across diverse segments, with a focus on:

  • Increasing the number of patients covered by health insurance plans

  • Serving international patients

  • Expanding services to accommodate patients under the Social Security Scheme (SSO) and exploring opportunities to serve the aging population

  • Renovating and upgrading existing hospital facilities to attract patients seeking aesthetic and wellness services

4) Identifying New Opportunities for Business Expansion

The Company is committed to achieving sustainable long-term growth by:

  • Exploring and evaluating new locations and projects with growth potential

  • Establishing and strengthening strategic partnerships and business collaborations

Other Information

NameDescription
Mission

"We committed to improvement, and provide healthcare with international standard for quality and safety, with empathy, accessible ,a leader in healing environment, focus on excellent patient experiences"

Material Changes & Developments

Introduction

In 2025, the Company has implemented its strategies by focusing on increasing the quality and safety of medical treatment in every care process, from before treatment, during treatment and after treatment, taking care of patients seamlessly at every step in order to become a leading international hospital and is committed to achieving operating results in line with the Company’s goals, with details as follows:

Material Changes & Developments

YearDescription
2,022

• Received the 1st renewal of JCI standardsReceived silver award in “Caring Services”

• Opened 2 specialist centers.

• Memorandum of cooperation for the Social Employment Promotion Project for disabled persons.

• Opened MRI (Magnetic Resonance Imaging) service

2,023

• Awarded a 5-star rating or "Excellent CG Scoring" for 2023 corporate governance.

• Received the “Outstanding Business” award in 2023 for being an important part in promoting and supporting the Region 4 Workers’ Rehabilitation Center.

• Received Global Healthcare Accreditation (GHA) with Excellence to Ratchaphruek Hospital for Medical Travel Services, a first in the Northeastern region.

• Announcement of the establishment of 1 subsidiary company, namely Kaen Phang Nga Company Limited, registered on August 21, 2023. The Company has a registered capital (initial) of 5 million baht, divided into 1 million shares, with a par value of 5 baht per share.

2,024

• Announcement of the Treasury Stock repurchase project, the maximum amount used for repurchasing shares is not more than 200 million baht, the amount to be repurchased is not more than 35 million shares (not more than 6.41 percent of all shares sold) From December 13, 2024 to June 12, 2025

• RPH has been assessed for the 2024 Corporate Governance Report of Thai Listed Companies (CGR) at the 5-star or “excellent” level (Excellent CG Scoring) for the 2nd consecutive year by the Thai Institute of Directors (IOD) with support from the Stock Exchange of Thailand. The assessment program has been participated by over 808 listed companies.

• Received the KKCC AWARD 2024 for outstanding business organizations and individuals for outstanding business organizations and individuals who have contributed to the growth of trade and business in Khon Kaen Province.

• Received the award for "Business that creates potential for Khon Kaen City, together with the Khon Kaen Chamber of Commerce".

The plaque of honor for RPH as “Outstanding Business” for the year 2024, which has been an important part in promoting and supporting the Rehabilitation Center for Workers in Region 4 for the 2st consecutive year.

• Increase the capital of the subsidiary company for the first time x May 2024 by increasing the registered capital by another 10 million baht, resulting in the company having a registered capital of 15 million baht, divided into 3 million shares at 5 baht per share.

• Increased the subsidiary's capital for the second time on December 1, 2024 by increasing the registered capital by another 50 million baht, resulting in the company having a registered capital of 65 million baht, divided into 13 million shares at 5 baht per share.

2,025
  • Ratchaphruek Hospital Public Company Limited implemented a share repurchase program (Treasury Stock) for financial management purposes in 2025. The Company repurchased a total of 15,593,000 shares, representing approximately 2.86% of the total issued shares, with an aggregate value of approximately THB 83.64 million. The share repurchase program was completed on 12 June 2025 through the Stock Exchange of Thailand.

  • Ratchaphruek Hospital Public Company Limited received the most recent Corporate Governance Report of Thai Listed Companies (CGR) assessment conducted by the Thai Institute of Directors (IOD), with the support of the Stock Exchange of Thailand and the Securities and Exchange Commission (SEC). The Company was rated at the “Very Good” level (4 stars), reflecting its strong corporate governance practices, transparency, and alignment with good governance principles.

  • The Company also received the Annual General Meeting (AGM) Checklist assessment score under the AGM quality evaluation program organized by the Thai Investors Association (TIA), in collaboration with the Stock Exchange of Thailand and the Securities and Exchange Commission, achieving a perfect score of 100 points (5 coins).

  • Ratchaphruek Hospital Public Company Limited successfully obtained its second accreditation from Joint Commission International (JCI), with the accreditation period effective from 26 July 2025 to 25 July 2028. This accreditation reflects the Company’s ongoing commitment to maintaining international standards of healthcare quality, patient safety, and excellence in medical services.

  • In addition, the Company participated in a collaborative energy conservation program for small and medium-sized commercial buildings, organized by the Department of Alternative Energy Development and Efficiency (DEDE), on 4 September 2025, demonstrating its commitment to energy efficiency and sustainable operations.

Use of Proceeds from Securities Offerings

Introduction

In 2025, the Company will not raise additional capital.

Is There Money Raised from a Securities Offering Still to Report On?

No

Commitments Made in the Registration Statement

Introduction

ในปี 2568 บริษัทฯ ไม่มีคำมั่น หรือข้อผูกพันใดหรือเงื่อนไขใด ๆ เพิ่มเติม

Are There Commitments or Conditions from an Offering or Listing?

No

Group Operating-Structure Policy

Description

As of December 31, 2025, the company has 1 subsidiary, Kaen Pha Nga Company Limited,

with registered capital of 150,000,000 baht, 30,000,000 shares. Consisting of 3 directors as follows:

1. Dr. Teerawat Srinakarin, M.D.

2. Professor Dr. vallop Laopaiboon, M.D.

3. Associate Professor Dr. Srichai Krusun, M.D.

List of shareholders, number of shares, percentage of shareholding (%)

Ratchaphruek Hospital Public Company Limited holds 29,999,998 shares, accounting for 99.98 percent.

Dr. Teerawat Srinakarin, M.D., holds 1 shares, proportion 0.01 %

Professor Dr. vallop Laopaiboon, M.D., holds 1 shares, proportion 0.01 %

Totaling 30,000,000 shares or 100%.

Companies Where the Company Holds ≥10%

Companies (≥10% Holding)

Company NameAddressProvinceZip CodeTelephoneBusiness TypeSecurity TypeSharesPaid-up Shares
KAEN PA-NGA COMPANY LIMITEDNo. 150/18, Moo 7, Mittraparb Road Nai-Mueang Sub-Distric, Mueang Khon Kane DistricKhon Kaen400000896223994Spacial Hospitals allowed patients to stay overnightCommon shares29,999,99830,000,000

Shareholders with Potential Conflict of Interest

Introduction

As of December 31, 2025, the Company has no joint venture companies.

Has Potential-Conflict Shareholder (Y/N)

No

Relationships Among Major Shareholders

Introduction

Mr. Teerawat Srinakarin serves as a Director and Chief Executive Officer of the Company and is also a major shareholder, holding more than 10 percent of the total issued and paid-up shares, according to the definition of the Office of the Securities and Exchange Commission (SEC). The Srinakarin Group holds shares in the Company both directly and indirectly, and Mr. Teerawat Srinakarin also serves as a director and executive in both the parent company and its subsidiaries within the Group.

Nevertheless, the Company has established a clear corporate governance structure by appropriately separating the roles, duties, and responsibilities of the Board of Directors, the management team, and the subsidiaries. In addition, the Company has put in place procedures for the consideration and approval of related party transactions in compliance with applicable laws and regulatory requirements to safeguard the interests of all shareholders.

Although Mr. Teerawat Srinakarin, in his capacity as Chief Executive Officer, is a major shareholder and the Srinakarin Group plays a significant role both in terms of shareholding and management of the Company and its subsidiaries, the Company places strong emphasis on checks and balances and good corporate governance. Key decisions are made through the Board of Directors’ decision-making process and are subject to oversight by independent directors and relevant sub-committees.

Furthermore, the Company has established policies and practices for managing related party transactions in a transparent, fair, and verifiable manner in order to prevent conflicts of interest and to enhance confidence among shareholders and all stakeholders.

Relationship Exists (Y/N)

No

Shareholders' Agreement

Introduction

The Company has no contract or agreement between the Company's major shareholders. on issues that may affect operations The said contract or agreement is acknowledged and signed by the Company and the Company does not conduct business by holding shares in other companies (Holding company).

Agreement Exists (Y/N)

No

Shareholding Diagram (Group Structure)

Does the company hold shares in other companies?

Yes

Subsidiaries

Company NameJuristic Persons / Holders
KAEN PA-NGA COMPANY LIMITEDRATCHAPHRUEK HOSPITAL PUBLIC COMPANY LIMITED · Voting rights percent: 99.98 · Shareholding proportion percent: 99.98

Income Structure

Product / Service Income

CategoryDescriptionThis YearThis Year %Last YearLast Year %2 Years Ago2 Years Ago %
Total revenue from operationsTotal revenue from operations1,162,000.031001,125,171.341001,160,586.27100
Other revenue from operations 000000
OtherOthers000000

Export Income

CategoryDescriptionThis YearThis Year %Last YearLast Year %2 Years Ago2 Years Ago %
Total revenueTotal revenue1,162,000.031001,125,171.341001,160,586.27100
DomesticDomestic1,162,000.031001,125,171.341001,160,586.27100
InternationalInternational000000

Other Income

Operating Other IncomeNon-Operating Other IncomeShare of Profit
1710 · As of year: 25743.07 · Description: Total other income · As of yesteryear: 24430.21 · As of year before yesteryear: 16941.8 · 1711 · As of year: 0.0 · Description: Other income from operations · As of yesteryear: 0.0 · As of year before yesteryear: 0.01712 · As of year: 25743.07 · Description: Other income not from operations · As of yesteryear: 24430.21 · As of year before yesteryear: 16941.81713 · As of year: 0.0 · Description: Share of profit · As of yesteryear: 0.0 · As of year before yesteryear: 0.0

Product / Service Characteristics

Introduction

The Company remains committed to operating with resilience, guiding the hospital through an era of transformation and competition. It is confident in maintaining its position as one of the most stable and sustainable hospitals, contributing to the broader society. The Company is dedicated to fulfilling its role as a responsible member of a quality community under the motto:"Whoever you are, we are here to understand and care for you with a human touch."

Business Type

3114

Business Groups

Business GroupDescription
Centers of Specialty (COS).

Centers of Specialty (COS)

At present, Ratchaphruek Hospital Public Company Limited provides comprehensive medical services covering both general medical care and increasingly complex specialized treatments. To enhance its medical capabilities and meet the evolving healthcare needs of patients, the Company has continuously developed specialized medical services through Centers of Specialty (COS). These centers aim to elevate the standard of medical treatment and provide more comprehensive and specialized healthcare services.

The hospital’s Centers of Specialty consist of:

  • Comprehensive Breast Center

  • Dialysis Center

  • Ear, Hearing and Balance Center

  • Mother and Child Center

  • Specialized Medical Clinics

1. Breast Center

The Breast Center provides comprehensive breast disease management through a multidisciplinary team consisting of surgeons, diagnostic radiologists specializing in breast imaging, radiation oncologists, medical oncologists specializing in chemotherapy, and pathologists. This collaborative approach ensures personalized treatment planning for each patient in accordance with international medical standards.

Services provided by the Breast Center include:

  • Clinical breast examination by specialist physicians

  • Breast screening using digital mammography and ultrasound

  • Fine Needle Aspiration (FNA) for breast cell sampling

  • Core needle biopsy under ultrasound guidance

  • Surgical procedures for diagnosis and treatment of breast diseases

In cases where a lump cannot be palpated, such as suspicious microcalcifications detected by mammography, physicians may utilize Needle Localization techniques to accurately identify the target area prior to surgery.

The center also provides Breast-Conserving Surgery for early-stage breast cancer patients, enabling breast preservation while maintaining effective treatment outcomes.

2. Dialysis Center

The Dialysis Center provides hemodialysis treatment using standardized dialysis machines that meet quality standards certified by the Nephrology Society. The center also offers Online Hemodiafiltration, a high-efficiency dialysis technology designed to improve the removal of metabolic waste from the body.

Services at the Dialysis Center include:

  • Hemodialysis for patients with acute kidney failure requiring urgent treatment

  • Continuous dialysis treatment for critically ill patients over a 24-hour period

  • Kidney biopsy services performed by experienced nephrologists

  • Dedicated waiting areas for patients’ relatives

In addition, the center provides amenities designed to enhance patient comfort during treatment, including personal entertainment devices for patients undergoing dialysis sessions.

3. Ear, Hearing and Balance Center

The hospital has established the Ear, Hearing and Balance Center to provide comprehensive diagnosis, treatment, and rehabilitation for patients with ear and balance disorders. Currently, the hospital is the first and only private hospital in Northeastern Thailand with a specialized team consisting of neurotologists, pediatric audiologists, and audiologists.

The center is equipped with advanced medical technologies to diagnose hearing loss and balance disorders in patients of all age groups.

Conditions treated at the center include:

  • Ear infections

  • Chronic otitis media

  • Cholesteatoma

  • Hearing loss

  • Sudden hearing loss

  • Tinnitus

  • Meniere’s disease

  • Benign paroxysmal positional vertigo (BPPV)

  • Otosclerosis

  • Acoustic neuroma

The center also offers specialized surgical procedures, including:

  • Intratympanic injection

  • Tympanostomy tube insertion

  • Tympanoplasty

  • Mastoidectomy for cholesteatoma treatment

  • Ossicular chain reconstruction

  • Ear canal expansion surgery

4. Mother and Child Center

The Mother and Child Center provides comprehensive healthcare services for mothers and children, covering prenatal care, pregnancy monitoring, childbirth preparation, and pediatric healthcare from infancy through adolescence. The center is staffed by obstetricians and pediatric specialists who closely monitor and care for both mother and child.

Key services include:

  • Antenatal care and pregnancy monitoring

  • Ultrasound diagnostic examinations

  • Fetal monitoring during pregnancy

  • Prenatal counseling and childbirth preparation programs

  • Childhood vaccination programs and developmental health promotion

The center also provides treatment for various pediatric conditions, including:

  • Allergies

  • Neurological disorders

  • Endocrine disorders

  • Pediatric heart diseases

  • Kidney and urinary tract disorders

Additionally, the center provides developmental monitoring, speech therapy services, and care for children with developmental delays or autism spectrum disorders.

5. Specialized Medical Clinics

In addition to the primary Centers of Specialty, the hospital also provides a variety of specialized clinics that offer diagnosis and treatment for both general and complex medical conditions. These clinics are supported by modern medical technologies and staffed by specialist physicians and experienced healthcare professionals.

The hospital emphasizes a Patient-Centered Care approach, prioritizing quality of care, patient safety, and compassionate service to ensure that patients receive the highest standard of medical treatment.

Outpatient Services (OPD)

Outpatient Department (OPD)

The Company provides outpatient services through 36 examination rooms, designed to accommodate patients seeking diagnosis and treatment across a wide range of medical specialties in an efficient and timely manner.

In addition, the Company has established an Acute Respiratory Infection Clinic (ARI Clinic) to provide dedicated services for patients presenting with respiratory symptoms, such as fever, cough, sore throat, runny nose, or shortness of breath. The clinic was established to separate patients with potential respiratory infections from general patients, particularly during the outbreak of COVID-19, in order to enhance safety measures and reduce the risk of disease transmission within the hospital.

Inpatient Services (IPD)

Inpatient Department (IPD)

The Company provides a variety of patient rooms designed to accommodate the diverse needs of patients and their families, ensuring comfort, privacy, and high standards of medical care. The hospital offers several types of rooms, including Deluxe Room, Super Deluxe Room, Junior Suite, Suite, Premier Room, Intensive Care Unit (ICU), Positive/Negative Pressure ICU, Nursery (Sick Infants), Nursery (Newborn), and Delivery Waiting Room.

The hospital building has designated floors 6 to 12 as inpatient wards (Inpatient Wards) to support efficient inpatient services. These areas are designed to facilitate medical care delivery while providing comfort and convenience for both patients and their families.

For patients who settle medical expenses via cash or credit card, as well as those whose medical expenses exceed the coverage limit under their insurance policies, the Company offers additional room rate discounts depending on the type of room selected, in order to facilitate access to services and help alleviate the financial burden on patients.

As of 31 December 2025, the Company had a total inpatient capacity of 198 beds.

Additional Service Scope

Additional Supporting Services

In addition to its core medical services, the Company provides various supporting services to enhance convenience and improve the overall service experience for patients, relatives, and visitors. These services include the following:

1. Kitchen and Food Service Center

To ensure that patients receive appropriate nutrition as part of their medical treatment, the Company engages an external professional food service provider to prepare meals for patients. Hospital nutritionists supervise and monitor the quality of the meals and determine appropriate dietary plans tailored to each patient's medical condition.

In addition, the hospital operates a food service center for visitors and the general public, providing convenience for patients, relatives, and visitors. The food center is located on the 1st floor near the Brahma Shrine entrance.

2. Emergency Ambulance Service

The hospital provides 24-hour emergency ambulance services for the transfer of emergency and critically ill patients. The ambulances are equipped with modern and high-standard life-saving medical equipment and are staffed by trained and experienced emergency personnel, enabling the hospital to provide timely and efficient emergency medical assistance.

3. International Marketing Department

The hospital has established an International Marketing Department to support international patients. The department includes staff who are proficient in several languages, including English, Chinese, and German, to provide accurate information regarding the hospital’s medical services to foreign patients.

In addition, the hospital provides interpreter services to facilitate communication between physicians and international patients. The team also assists with appointment coordination, treatment arrangements, and travel facilitation for patients traveling from overseas, ensuring a high-quality service experience that meets international standards.

4. Customer Service Center

The hospital operates a Customer Service Center to assist patients and visitors by providing information about medical services, physician appointments, and service procedures. The center also coordinates with relevant departments within the hospital to ensure that patients and their relatives receive convenient, efficient, and satisfactory services.

5. Insurance Coordination Center

The hospital has a dedicated unit responsible for coordinating healthcare benefits and insurance services. This center assists patients who use health insurance or other healthcare benefits by verifying coverage, coordinating with insurance companies, and providing guidance regarding coverage conditions and claim procedures.

This service helps ensure continuity of care while reducing administrative burdens for patients and facilitating a smoother treatment process.

Research & Development

Has R&D Policy (Y/N)

No

Introduction

In 2025, the Company has no research investment plan, but considering the size of the business, responding to the needs of stakeholders and being ready to support economic, social and environmental changes, which lead to increased opportunities and competitiveness.

R&D Cost — Label

Research and development (R&D) expenses over the past 3 years (Million Baht)

R&D Cost — This Year

0.0

R&D Cost — Last Year

0.0

R&D Cost — 2 Years Ago

0.0

Assets Used in the Business

Introduction

The assets used in the business operations of the Company and its subsidiaries, according to the book value as of December 31, 2025, are as follows:

Permanent Assets — Description

The Company divides fixed assets into 3 types: land, buildings and equipment.

Permanent Assets — Appraisal

AssetOwnershipObligationAppraisal ValueDescription
Land 9 plotsOwnershipNone78.84
Land 9 plots (are 4-3-93.5 rai) Location on Khon Kaen Province
Land 2 plotsOwnershipMortgage135.4
Land 2 plots (are 33-0-39 rai) Location on Khon Kaen ProvinceThe property is under mortgage. Which is under bank mortgage
Building OwnershipNone0
Building with area 7,412 square meters. Location on Mittraphap Road, Mueang, Khon Kaen
Building (14 floors)OwnershipMortgage470.11
Building 14 floors Total usable area 36,000 square meters. Location on Mittraparb Rode, Mueang, Khon Kaen
Land 4 plotsOwnershipNone12
4 plots of land, total area (5-2-45.7 rai) Location on Chum Pae, Khon Kaen Province
Asset in Progress/installationOwnershipNone61.51
Building 4 floors Total usable area 6,886 square meters. Location on Mittraphap Road, Mueang, Khon Kaen

Intangible Assets — Description

• Intangible assets of the Company and its subsidiaries

As of December 31, 2025, the Company and its subsidiaries had net intangible assets 16.11 million Baht, most of which were computer program costs used in the hospital operations and related businesses of the Company and its subsidiaries.

Intangible Assets — Appraisal

AssetTypeType (if Other)Appraisal ValueDescription
Company and its subsidiaries had net intangible assets Software16.11
As of December 31, 2025, the Company and its subsidiaries had net intangible assets 16.11 million Baht, most of which were computer program costs used in the hospital operations and related businesses of the Company and its subsidiaries.
Assets of the Company and its subsidiaries - Leasehold RightsOthersProperty rights-lease contract3.9
Right of Use-Lease As of December 31, 2025, the net book value of Right of Use-Lease was 3.90 million baht, most of which were medical equipment and tools used in hospital operations.

Has Subsidiaries Investment Policy (Y/N)

Yes

Subsidiaries Investment Policy — Description

Policy for investment in subsidiary and associated company and policy for management of such companies, including control and governance mechanisms of Ratchaphruek Hospital Public Company Limited

Policy for investment in subsidiary and associated company and policy for management of such companies, including control and governance mechanisms The Company manages its business by upholding Guidelines for Good Corporate Governance prescribed by the Stock Exchange of Thailand (“SET”). In investment decisions, not only considering return to all stakeholders, but also the Company operates its business in line with Guidelines for Good Corporate Governance prescribed by the SET and the Office of the Securities and Exchange Commission (“Office of the SEC”), which is a factor of importance to the Company. The Company realizes that adopting the Guidelines for Good Corporate Governance is a method for control and mechanism which will lead to investment governance and transparent and verifiable management system. This will allow the Company as major shareholder to control, manage and be responsible for the operations, including determination of directions for invest company as if it was a unit of the Company. In addition, the Company will be able to monitor management of such business in order to protect its benefits from investment. Such measures for corporate governance will provide added-values and assurance to stakeholders with regards to continuity and sustainability of the Company’s investment.

The Company, therefore, sets this policy for investment in subsidiary and associated company and policy for management of such companies to be in line with rules regarding governance of operations of subsidiary and associated company pursuant to the Notification of the Capital Market Supervisory Board No. TorChor. 28/2551 Re: Application for and Approval of Offer for Sale of Newly Issued Shares and Guidelines for Good Corporate Governance of the SET, the details of which are as follows:

Policy for investment in subsidiary and associated company

The Company has a policy to invest in subsidiary or associated company which support the Company’s business operations and of which investment would create synergy, generate additional revenue streams, and increase profitability of the Company. The Company will consider proportion of investment, expected profitability, possible risks and financial status of the target companies prior to making investment decision. Any investment decision must obtain a resolution of the Company’s board of directors or shareholders, as the case maybe, approving the transaction. The Company shall appoint qualified representative as director of investee company in order to set key policies and for good corporate governance of subsidiaries and associated company.

1. The Company has set guidelines in exercising rights by its representatives in shareholders’ meeting of subsidiary and associated company to be consistent with the proportion of shareholding in subsidiary and associated company.

This is also for compliance with Guidelines for Good Corporate Governance and maintain maximum benefits to the Company, its subsidiaries and associated companies, and other shareholders.

(1) Certification of minutes of the general meeting of shareholders and extraordinary general meeting of shareholders

- Approve if draft minutes records all details of the meeting completely and accurately.

- Abstain if the Company’s representative did not attend the meeting.

(2) Certification of annual financial statements

- Approve if auditor expresses his/her opinion unconditionally or with condition which is not material to the financial statements and does not have an impact on overall benefits of the shareholders.

- Disapprove if auditor expresses opinion or makes an observation that any part of the financial statements may be incorrect.

(3) Appointment of directors and determination of directors’ remuneration Appointment of directors

- Approve if the person is nominated by resolutions of the Company’s board of directors’ meeting and has qualifications and does not possess any prohibited characteristics as specified under the laws or relevant regulations of the Securities and Exchange Commission. The person nominated shall have knowledge, capabilities, and experience beneficial to the business operations, can devote sufficient time as director of the company, and perform his/her roles and responsibilities as director with attention. The consideration whether any person is suitable to act as director of the company shall be on an individual basis.

- Disapprove if it is a reappointment of existing director and such director lacks any qualification and possesses any prohibited characteristic as specified under the laws or relevant regulations of the Securities and Exchange Commission, or such person lacks knowledge, capabilities and experience beneficial to the business operations, or such person cannot devote sufficient time as director of the company and did not perform his/her roles and responsibilities as director with attention without reasonable causes. The appointment of new director in associated company or subsidiary shall not be contrary to the Company’s rules regarding controlling business specified in Item

2.1 and any other relevant laws. Determination of directors’ remuneration

- Approve if the proposed directors’ remuneration is appropriate for roles, responsibilities and performance of the Board of Directors as reflected through operating results and operating performance and/or financial positions of such subsidiary or associated company.

- Abstain if the proposed remuneration is a special payment of undisclosed amount or ESOP which would generate significant dilution effect to subsidiary or associated company, or is not in compliance with the rules of supervisory agencies and/or is not appropriate for roles, responsibilities and performance of the Board of Directors as reflected through operating results and operating performance and/or financial positions of such subsidiary or associated company.

(4) Appointment of auditor and determination of audit fees

- Approve if after due consideration, the auditor and the audit firm is reliable and able to perform their roles in auditing and reviewing financial statements correctly and express their opinion independently. The audit fees proposed shall be at a level comparable to similar audit firms.

- Abstain if there is any doubt in reliability or independency of the auditor or the audit fees is significantly different from the previous year’s audit fees without reasonable cause.

(5) Appropriation of profits

- Approve As proposed by the board of directors of subsidiary and associated company and consistent with the dividend policy and not contrary to the relevant laws.

- Disapprove if payment of dividends is not in line with financial positions, future plan, and/or any other relevant factors of subsidiary and associated company.

(7) Approval of other matters apart from Items (1) – (6)

- Approve agenda which is beneficial to subsidiary or associated company or to shareholders and with fair and reasonable proposals, and the conduct of business shall be with ethics and in accordance with the relevant laws. The approval process of such matter shall be in accordance with the laws and the Company’s Articles of Association.

- Disapprove if a transaction is not in the ordinary course of business and is being considered without clarifications and reasons and necessity for the entry into the transaction

(8) Approval of any matter which was not specified as one of the agenda items prior to the meeting May disapprove consideration of any other matter which was not specified as one of the agenda items prior to the meeting, particularly matter of significant importance, as there should be considerable time spent on studying important information which is critical to decision-making. Such matter or agenda may be proposed for consideration during the next shareholders’ meeting.

2. The Company determines management structure of subsidiaries and associated companies in order to oversee management and operations of its subsidiaries and associated companies as if they were units of the Company. To look after its investment, the Company shall have the following procedures for monitoring the management of its subsidiaries and associated companies:

2.1 Nomination of its representative as director of subsidiary and associated company

The Company shall nominate its representative, who has been approved by resolution of the Company’s Board of Directors, as director of subsidiary and associated company at the minimum number corresponding to its proportion of shareholding in such subsidiary and associated company.

The nominated person shall have qualifications, roles and responsibilities and shall not have prohibited characteristics as specified under the notifications of the Securities and Exchange Commission and the Stock Exchange of Thailand regarding the lack of trustworthiness of directors and management of the company.

2.2 Roles and responsibilities of director of subsidiary and associated company Person who is nominated by resolution of the Company’s Board of Directors as director of subsidiary and associated company shall have the following roles and responsibilities:

2.2.1 Director of subsidiary and associated company shall have the roles and responsibilities as determined by the board of directors of subsidiary and associated company and/or the shareholders’ meeting of subsidiary and associated company. Director of subsidiary has discretion to consider and vote during the board of directors’ meeting of subsidiary for matters relating to general management and normal business operations of the subsidiary as directors and management of such subsidiary deems appropriate for the utmost benefits of the subsidiary and the Company.

However, consideration and voting of the below matters are considered important matters. The person appointed by resolution of the Board of Directors as director of subsidiary cannot exercise his/her discretion in voting for those matters during the board of directors’ meeting of the Company’s subsidiary. Such person shall obtain a prior consent from the Board of Directors’ meeting or the shareholders’ meeting of the Company (as the case may be).

A. Entry into a transaction with related person of subsidiary pursuant to the Notification of the Board of Governors of the Stock Exchange of Thailand Re: Disclosure of Information and Other Acts of Listed Company Concerning Connected Transactions B.E. 2546 (2003) and the Notification of the Capital Market Supervisory Board No. TorChor. 21/2551 Re: Rules on Connected Transactions (“Connected Transaction Notifications”)

B. Entry into a transaction which is an acquisition or disposal of assets of the subsidiary pursuant to the Notification of the Board of Governors of the Stock Exchange of Thailand Re: Disclosure of Information and Other Acts of Listed Company Concerning Acquisition or Disposal of Assets and the Notification of the Capital Market Supervisory Board No. TorChor. 20/2551 Re: Rules on Entering into Material Transactions Deemed as Acquisition or Disposal of Assets (“Acquisition and Disposal of Assets Notifications”).

C. Entry into significant transactions pursuant to Items 2.2.4, 2.2.5 and 2.2.6

2.2.2 Director of subsidiary and associated company must perform his/her duties with responsibilities, care and honesty, and shall comply with the laws, objectives, articles of association of subsidiary or associated company, resolutions of the board of directors’ meeting and the shareholders’ meetings, and policies of the Board of Directors of which the board of directors of subsidiary has approved as per the resolutions of the Board of Directors.

2.2.3 Director of subsidiary has a duty to disclose to the Company complete and accurate information regarding financial status and operating performance, connected transactions, and material acquisition or disposal of assets of subsidiary within the period prescribed by the Company. Acquisition or disposal of any material assets should take the relevant rules and regulations of the Office of the SEC and SET into consideration.

2.2.4 Apart from entry into transactions in accordance with Connected Transaction Notifications or Acquisition and Disposal of Assets Notifications, entry into the following transactions are deemed material. Subsidiary has a duty to present information regarding such type of transaction to the Company for approval by the meeting of the Executive Committee of the Company prior to considering it in its meeting of the board of directors. In addition, director appointed by the Company must obtain approval from the Company’s Board of Directors prior to voting for the following matters:

(1) transfer or waiver of benefits with the value exceeding the authorized limit of the Executive Committee of the Company in approving expenses, including waiver of material rights and claim to those causing damages to subsidiary;

(2) sell or transfer business of subsidiary, whether wholly or material part thereof, to third party;

(3) purchase or acquire business of another company as subsidiary’s own business in the proportion which is considered material;

(4) entry into, amend or terminate agreement relating to lease of business by subsidiary, whether wholly or material part thereof, including authorization of third party to manage business of subsidiary or merger of business with third party with an objective to share profit and loss;

(5) lease or hire-purchase of business or assets of subsidiary, whether wholly or material part thereof;

(6) borrowing, lending, providing credits, guarantees, entry into any juristic which will result in subsidiary carrying significantly increased financial burden due to the third party lacks liquidity or is not able to perform his debt obligations or any other financial supports to any person which is not within the ordinary course of business;

(7) payment of annual dividends and interim dividends (if applicable) of subsidiary;

(8) cessation of subsidiary’s business where the calculation of transaction size of subsidiary’s business which is being ceased compared to size of the Company according to the Acquisition and Disposal of Assets Notifications must fall within the category which requires approval from the Board of Directors of the Company; (9) amendment of articles of association of subsidiary.

2.2.5 The following matters are important matters of which subsidiary requires to obtain prior approval from the Company’s shareholders meeting:

(1) if subsidiary agrees to enter into transaction with its related party or acquire or dispose its assets where the relevant rules of the Capital Market Supervisory Board and the Board of Governors of the Stock Exchange of Thailand shall apply, mutatis mutandis. The transaction size compared to size of the Company calculated according to such rules must result in the transaction size which requires approval from the Company’s shareholders meeting;

(2) capital increase by issuing and allotment of subsidiary’s newly issued shares, including decrease of registered capital which is not proportionate to existing shareholding and would result in decrease of the Company’s shareholding in subsidiary at any level, whether directly or indirectly, by 10% or more of the paid-up capital of subsidiary or would result in decrease of the Company’s shareholding in subsidiary at any level, whether directly or indirectly, to less than 50% of the paid-up capital of such subsidiary;

(3) any other act which would result in decrease of the Company’s shareholding in subsidiary at any level, whether directly or indirectly, by 10% or more of the paid-up capital of subsidiary or would result in decrease of the Company’s shareholding in subsidiary at any level, whether directly or indirectly, to less than 50% of the paid-up capital of such subsidiary;

(4) cessation of subsidiary’s business where the calculation of transaction size of subsidiary’s business which is being ceased compared to size of the Company according to the relevant rules of the Capital Market Supervisory Board and the Board of Governors of the Stock Exchange regarding acquisition or disposal of assets shall apply, mutatis mutandis, and the transaction size calculated according to such rules must fall within the category which requires approval from the Company’s shareholders meeting;

2.2.6 Apart from transactions under Items 2.2.4 and 2.2.5, if subsidiary will enter into any other transaction which is not in its ordinary course of business and/or any transaction which will materially affect itself, such transaction must obtain prior-approval from the Board of Directors of the Company or the Company’s shareholders meeting. The subsidiary shall comply with requirements for the transaction size calculated in accordance with the rules prescribed by the Acquisition and Disposal of Assets Notifications.

3. Directors and management of subsidiary must disclose and deliver information regarding personal of interest, including interest of their related persons, in relation to any transaction or in other business which might raise conflict of interest with the Company, subsidiary, board of directors of subsidiary or person authorized by subsidiary within the period of time as prescribed by subsidiary. Such information shall be used as supporting information for decision making or passing any approval by considering overall benefits of subsidiary and the Company as critical factors. Directors and management of subsidiary shall not participate in the consideration of any matter of which they have personal interest or conflict of interest.

4. Directors and management of subsidiary, including any person related to such directors and management, have the duty to inform to the board of directors of subsidiary relationship and transaction with subsidiary which might raise conflict of interest and avoid entering into transaction which might raise conflict of interest with subsidiary.

The board of directors of subsidiary has the duty to inform such matter to the Company for acknowledgement. The following acts, which result in directors, management or any person related to subsidiary gaining financial benefits other than that ordinarily received or cause damages to subsidiary, are presumed to be material conflict of interest with subsidiary:

(a) any transaction between subsidiary and director, management or any connected person which is not in compliance with rules regarding connected transactions; (b) use of known information of the Company and subsidiary, except information which has been publicly disclosed; or

(c) use of asset or business opportunity of the Company and subsidiary in a way which violates the rules or general practice as prescribed by the Capital Market Supervisory Board.

5. Subsidiary must deliver to the Company information or documents relating to its operations upon appropriate request.

6. If the Company finds any material issue, it may request subsidiary to clarify and/or deliver document as supporting information for its consideration.

7. Directors, management, employees, staff or authorized persons of subsidiary, including their spouse and minor children, are not allowed to use internal information of the Company and subsidiary, whether such information is obtained through performance of duties or through any other method or, whether or not such information has significant impact on the Company and subsidiary, for their own benefits or others, whether directly or indirectly and whether or not for consideration.

8. Directors, management of, or any person related to, subsidiary may enter into a transaction with subsidiary only upon receiving approval from the Board of Directors of the Company or the Company’s shareholders meeting as required based on transaction size calculated pursuant to the rules of the Connected Transaction Notifications. Exceptions apply where transaction is with terms and conditions similar to transaction with other counterparties under the same circumstances, the position as director, management or related person, as the case may be, do not have influence on the transaction, and trade terms and conditions of the transaction have been approved by the Board of Directors of the Company or in line with principles as approved by the Board of Directors.

Marketing Policy & Competition

Reporting Mode

3117

Marketing Policy (Overall)

Marketing Policy and Brand Strengthening

Patient Segmentation

The Company provides medical services to several key patient segments, consisting of:

Self-Pay Patients

This group includes residents and employees working in Khon Kaen Province who have strong confidence in the hospital’s medical quality and the expertise of its physicians. The majority of the hospital’s patients fall within the middle-to-upper income segment, with sufficient purchasing power to cover medical expenses independently.

Insurance and Contract Patients

This group consists of corporate contract partners that have agreements with the hospital to provide medical services or health check-ups at negotiated rates. The contracting organizations are responsible for the payment of medical expenses in accordance with the terms specified in the contracts.

This segment also includes individual patients who are entitled to reimbursement through insurance policies, where insurance companies have agreements with the hospital to cover medical expenses in accordance with applicable insurance regulations.

Government Scheme Patients

This group comprises patients who receive treatment under government healthcare benefits. The hospital facilitates direct reimbursement according to the patient’s eligible benefits. Examples include reimbursement through the Comptroller General’s Department, advance surgery programs, hemodialysis services under government and social security schemes, and patients under specific government healthcare programs.

In 2025, the distribution of patients by revenue group was as follows:

  • Self-pay patients: 48.31%

  • Insurance patients: 46.34%

  • Government scheme patients: 5.15%

  • Others: 0.20%

Brand Image of Ratchaphruek

The Company continuously enhances its corporate image in order to strengthen brand recognition among the residents of Khon Kaen Province. Various marketing campaigns have been implemented through a proactive marketing strategy, focusing on both brand building and patient base expansion.

The Company aims to attract new patients both domestically and internationally while maintaining strong relationships with existing patients, including general patients and corporate contract partners. This is achieved through patient relationship management initiatives and regular marketing activities conducted both internally and externally.

The Company utilizes multiple communication tools, including printed media and digital platforms, to disseminate healthcare information and promote hospital services.

Efforts have also been made to strengthen brand recognition for “Ratchaphruek” among key target groups such as teenagers, working adults, and mothers with children, as these groups represent potential demand for healthcare services in the future.

Marketing communication strategies include activities and campaigns designed to align with modern media consumption behaviors, including promotion through:

  • Social media platforms

  • Influencers and digital content

  • Billboards and LED signage installed at strategic locations

In the current digital era, where negative news can spread rapidly through social media, the Company has established a dedicated monitoring team to closely track public sentiment. If potentially negative information arises, the Company promptly investigates the issue and takes corrective action to clarify and communicate accurate information to the public in a timely manner.

Policy on Improving Treatment Quality

The Company’s policy aims to enhance the hospital’s Centers of Specialty (COS) in order to strengthen the hospital’s medical capabilities.

The Company focuses on recruiting and developing specialists across various medical fields while integrating advanced and efficient medical technologies into clinical practice. Medical services are delivered by a team of highly qualified, experienced, and skilled healthcare professionals to ensure high-quality patient care.

Pricing Policy

The Company adopts a pricing policy that reflects the type and complexity of medical treatments while remaining competitive within the local healthcare market.

Pricing for medical services is set at a level comparable to other hospitals within the same market segment in the area. For inpatient accommodation, room rates are determined based on market comparisons with hospitals located in similar or nearby locations. The room charges may vary depending on the facilities and amenities provided.

The hospital group has also studied the feasibility of adjusting certain service fees, particularly nursing service fees, to align with other hospitals at the same service level. Although the hospital has significantly developed its medical facilities and technologies, current service fees remain relatively competitive compared to other hospitals in the same category.

Distribution and Service Channels

The Company provides multiple distribution and service channels to accommodate different patient groups, including self-pay patients, insurance or corporate contract patients, and government scheme patients.

Service channels are divided into online channels and on-site hospital services, ensuring a diversified approach that reduces reliance on any single service channel. This strategy helps minimize the risk of losing patients and allows the hospital to reach new patient segments across all age groups.

The Company has prioritized the development of online healthcare access channels, which are developed through the hospital’s internal systems. These channels allow patients to conveniently access services, review healthcare packages, and explore treatment options before scheduling medical appointments.

Examples of online service channels include:

  • Telemedicine services responding to the “New Normal” lifestyle

  • Healthcare package purchases through the hospital website

  • Communication and service access via Line and Facebook Fanpage

In the future, the Company may expand distribution through additional online platforms and digital marketplaces in order to respond to rapidly evolving consumer behavior and healthcare service demands.

Industry & Competition (Overall)

Overview of the Private Hospital Industry in Khon Kaen Province

Khon Kaen is widely recognized as a major economic, educational, and healthcare hub of Northeastern Thailand. The province has well-developed healthcare infrastructure, including large public hospitals, university hospitals, and several private hospitals. As a result, Khon Kaen serves as an important medical center for residents within the region, as well as patients from nearby provinces and neighboring countries within the Greater Mekong Subregion (GMS).

In 2025, the private hospital industry in Khon Kaen continued to show steady growth, in line with the overall expansion of Thailand’s healthcare sector. Several key factors support this growth, including the transition toward an aging society, the increasing prevalence of non-communicable diseases (NCDs), and rising demand for higher-quality healthcare services. These trends are expected to contribute to the long-term growth potential of the private healthcare sector.

In addition, both the public sector and academic institutions have promoted initiatives aimed at positioning Khon Kaen as a regional Medical Valley and Wellness Hub, further strengthening the province’s role as a center for healthcare and medical services. This development is expected to increase demand for medical services in the area in the coming years.

Regarding the competitive landscape, Khon Kaen is home to several private hospitals providing medical services. Major private healthcare providers in the province include:

  • Khon Kaen Ram Hospital

  • Bangkok Hospital Khon Kaen

  • Ratchaphruek Hospital Public Company Limited

These hospitals represent the key private healthcare providers in the province and continue to enhance their medical capabilities through the development of specialized medical centers, the adoption of advanced medical technologies, and improvements in service quality in order to meet the increasingly diverse needs of patients.

However, the private hospital industry in Khon Kaen also faces intensifying competition. This includes the expansion of existing private hospitals as well as the continued development of large public hospitals with strong capabilities in the province. One example is Khon Kaen Hospital, a regional referral hospital with more than 1,000 inpatient beds that plays a significant role in providing healthcare services to residents across Northeastern Thailand.

Given these factors, private hospital operators in Khon Kaen must continuously adapt their business strategies. This includes strengthening specialized medical centers, adopting advanced medical technologies, enhancing service quality, and differentiating patient experience in order to improve competitiveness and effectively respond to the growing demand for healthcare services.

Overview of the Private Hospital Business

The private hospital business is a highly competitive industry, as competition exists not only among private hospitals operating at similar service levels but also with public healthcare providers such as government hospitals and after-hours specialty clinics.

In addition, medical services today face increasingly intense competition due to the ongoing consolidation strategies of large hospital groups. Such mergers and acquisitions may create advantages in terms of operational costs and allow these hospital groups to offer a wider range of medical services that better meet the needs of patients.

Nevertheless, the Company focuses on delivering efficient healthcare services and management through a diverse team of specialized medical professionals and the use of modern medical equipment, while maintaining reasonable and appropriate service fees.

Number of Competitors and Company Size

Khon Kaen Province and its surrounding areas present significant growth opportunities for healthcare providers and are considered a high-potential market for hospital businesses. The province has a relatively large population and serves as an educational hub of Northeastern Thailand, with Khon Kaen University as one of the largest universities in the region.

As a result, a large number of academic personnel, staff, and students reside and work in the area. In addition, the population continues to grow steadily, making the province an attractive market for private hospital operators. Consequently, competition for market share among hospitals in the area is expected to intensify.

Apart from competition among private hospitals themselves, which include hospitals affiliated with the Bangkok Dusit Medical Services network and the Ramkhamhaeng Hospital Group, competition has also increased from university hospitals that serve as major medical training institutions.

One notable development is the construction of the Advanced Medical Service Center Building, a large-scale project of Khon Kaen University that is expected to become a major medical hub in the region. The facility is anticipated to commence operations in 2026.

Service Excellence

Despite the highly competitive environment in the private hospital sector, particularly with the expansion of public hospitals and medical schools, the Company remains committed to operating its business fairly and maintaining reasonable service fees without engaging in unnecessary price competition.

The Company has successfully maintained its position as one of the leading private hospitals in Khon Kaen for many years. This achievement reflects the trust and confidence of patients and service recipients from Khon Kaen and nearby provinces.

The hospital emphasizes excellence in the following areas:

  • Professional medical treatment and services

  • A multidisciplinary team consisting of physicians, nurses, and allied healthcare professionals

  • High-quality healthcare services and treatment standards

International healthcare accreditation standards

Competitive Strengths and Medical Service Capabilities

International Healthcare Standards

Ratchaphruek Hospital Public Company Limited has now received JCI accreditation for the second time under Edition 8, demonstrating internationally recognized standards in quality and patient safety. This achievement also enhances the hospital’s readiness to serve international patients, particularly those from ASEAN countries, China, and Lao PDR.

The Company has therefore developed marketing strategies, service quality improvements, and personnel development programs to support this patient segment. The hospital emphasizes patient-centered care, providing seamless healthcare services before, during, and after treatment, while maintaining reasonable service fees for patients.

The hospital has received accreditation from the Joint Commission International (JCI) of the United States, an organization responsible for evaluating international standards of healthcare quality and patient safety. The Company prioritizes the safety of patients and healthcare personnel as its highest priority.

To support this commitment, the Company has established healthcare quality policies and operational guidelines in accordance with international JCI standards. These practices aim to enhance the capabilities of medical personnel, continuously improve patient care, and reduce potential risks related to patient safety complaints.

The Company also places strong emphasis on patient satisfaction. Regular patient satisfaction surveys are conducted, and the results are summarized on a quarterly and annual basis. These insights are used to improve service quality and operational efficiency, which not only enhances patient satisfaction but also encourages repeat visits.

Service Utilization Rate

Service utilization is evaluated by comparing the actual service volume with the hospital’s maximum service capacity, categorized into outpatient and inpatient services.

For the years 2023–2025, outpatient utilization rates were 23.99%, 22.55%, and 22.49%, respectively. The relatively moderate utilization rate reflects the hospital’s preparation of additional service space to accommodate future growth.

For inpatient services, the bed occupancy rates for the years 2023–2025 were 68.84%, 62.42%, and 64.89%, respectively. These figures are partly due to the expansion of the hospital’s facilities, which increased the number of inpatient rooms.

On 15 August 2023, the Company opened an additional inpatient ward (Ward 9) on the ninth floor, consisting of 15 rooms and 185 beds, to support growing patient demand. Subsequently, in early 2024, the hospital increased its operational capacity to 198 licensed beds.

Patient Segments and Target Groups

The Company’s key service recipients can be categorized into the following main groups:

  • Self-pay patients, accounting for approximately 48.31% of hospital revenue in 2025

  • Contracted corporate and insurance patients, accounting for approximately 48.34% of hospital revenue in 2025

  • Government scheme patients and patients under the Road Accident Victims Protection Act, accounting for approximately 5.15% of hospital revenue in 2025

Procurement of Products & Services

Reporting Mode

3117

Procurement (Overall)

Recruitment of Physicians and Nursing Personnel

The Company has a policy to recruit physicians with specialized expertise in various medical fields, as well as other healthcare professionals such as nurses, medical technologists, physiotherapists, and allied health personnel. This approach ensures that patients receive comprehensive, high-quality medical services.

Over the years, the Company has been able to continuously attract experienced and qualified medical professionals to join the organization. The Company also places strong emphasis on retaining its healthcare personnel by providing appropriate compensation and benefits, creating a positive working environment, and fostering a supportive organizational culture.

In addition, the Company actively supports continuous professional development through academic conferences, medical seminars, and regular training programs for physicians, nurses, and healthcare personnel. These initiatives aim to enhance medical knowledge, keep staff updated with the latest medical advancements, and ensure the highest standards of patient safety and care.

Procurement of Pharmaceuticals and Medical Supplies

Pharmaceuticals and medical supplies are among the most critical inputs for hospital operations. Therefore, the Company places significant importance on implementing strict procurement processes, beginning with the drug purchasing procedure.

The Company has established a Drug Selection and Procurement Committee, consisting of physicians, pharmacists, procurement staff, and accounting personnel. This committee is responsible for overseeing the appropriate sourcing of pharmaceuticals and managing the inventory control system within the hospital.

The procurement process includes careful evaluation of product pricing, effectiveness, and quality to ensure sufficient supply for patient care. As pharmaceuticals and medical supplies represent key components of hospital operations, the Company adopts a policy of sourcing medicines and medical supplies from multiple manufacturers and distributors.

Most pharmaceutical procurement is conducted domestically, which helps ensure stable supply and reduces the risk of shortages.

Furthermore, the Company does not rely heavily on any single supplier. From 2018 to 2025, purchases from any single pharmaceutical or medical supply distributor did not exceed 30% of the total procurement value, and the Company has no contractual commitments to purchase pharmaceuticals or medical supplies exceeding 30% of future procurement value from any single supplier.

Medical Equipment and Technology

As diseases become increasingly complex, modern medical equipment and technology are essential to ensure adequate and high-quality patient care.

The Company recognizes the importance of investing in advanced medical equipment, even though such investments require substantial capital expenditure. All investment decisions are therefore carefully evaluated to ensure that the equipment is necessary, of high quality, and aligned with patient demand and medical service capacity.

In practice, the Company procures medical equipment through authorized distributors in Thailand, where purchase prices are clearly defined and after-sales service agreements are established to ensure operational efficiency and long-term value.

Modern, efficient, and internationally standardized medical equipment plays a crucial role in enhancing the quality of patient treatment. As a result, the Company closely monitors advancements in medical technologies through its specialist physicians in each medical field.

In addition, the Company carefully selects reputable manufacturers and distributors that meet international standards, ensuring that the hospital acquires high-quality equipment at reasonable prices along with reliable after-sales services.

Raw Material Acquisition (Overall)

The procurement of raw materials and suppliers,

including medicines, medical supplies, and consumables used in medical treatments, is entirely sourced from domestic manufacturers or distributors. A dedicated committee is assigned to evaluate and approve the introduction of these materials for use in the hospital.

Transparent Procurement Practices To ensure transparency in the procurement process,

Ratchaphruek Hospital Public Company Limited has established policies to build trust and integrity among stakeholders. Effective supply chain management is recognized as a key factor in achieving sustainable business success. The procurement process includes a comparative evaluation to select quality partners and suppliers. The Company is committed to conducting business under the principles of good corporate governance, guided by ethics and honesty. All suppliers are required to adhere to the Supplier Code of Conduct.

So, The Board of Directors treats suppliers with fairness and mutual benefit, guided by the following policies and practices:

1) A supplier selection system ensures compliance with laws, adherence to safety and occupational health standards, and environmental friendliness. Suppliers are treated based on fair competition, equality, and mutual respect.

2) Confidentiality of supplier information is maintained and not misused for personal or related parties' benefit.

3) Positive relationships and mutual understanding are fostered, with knowledge exchange to co-develop and enhance the value of products and services for mutual growth.

4) Trade agreements are honored, and accurate information is provided. In cases where obligations cannot be met, negotiations with suppliers are initiated in advance to find solutions and prevent damage.

5) The Company does not request, accept, or agree to receive any assets or benefits beyond trade agreements.

The supplier selection and evaluation process includes a monitoring system through an Approved Vendor List, using preliminary questionnaires and follow-up inspections to ensure selected suppliers are capable and reliable. Annual evaluations are conducted to ensure ongoing supplier performance.

Production Policy (Overall)

The utilization rate of the patient group is assessed from the actual number of services compared to the maximum service potential, divided into outpatient and inpatient groups. In 2023-2025, the outpatient group had a utilization rate of 23.99 percent, 22.55 percent, and 22.49 percent, respectively. However, the examination room utilization rate is not high because the area is prepared for future services. Meanwhile, the inpatient group had a utilization rate (bed occupancy rate) of 68.84 percent, 62.42 percent, and 64.89 percent, respectively, in 2023-2025. This is due to the opening of the current hospital building, which has an increased number of inpatient rooms.

Outpatient services (OPD)

- Number of examination rooms (average) 36 examination rooms, 365 days of service

- Maximum outpatient capacity 709,560 times **

- Actual outpatient treatment 159,559 times

- Service utilization rate 22.49 percent

Remarks : ** The maximum outpatient capacity is approximately 54 times per room per day.

Inpatient Group Services (IPD)

Inpatient Group (IPD) 2025, the number of beds actually used (average) 171 beds, 365 days

- Maximum inpatient capacity 62,415 beds

- The number of inpatients actually treated 40,499 beds

- Service utilization rate 64.89 percent

- Average total service utilization rate 64.89 percent

Distributors (Overall)

In 2025, the top 3 distributors that the company has contacted to trade are:

1) Zuellig Pharma Co., Ltd. Purchase value of 65,197,494.45 baht

2) DKSH (Thailand) Co., Ltd. Purchase value of 42,210,282.42 baht

3) Dimentic Co., Ltd. Purchase value of 9,398,547.20 baht

Number of Raw-Material Distributors (Overall)

3

Production Capacity (Overall)

ItemUnitUnit (if Other)UsedCapacity
Number of outpatients (OPD) (actual treatment)Otherstimes22.49159,559
Maximum outpatient capacityOtherstimes0709,560
Number of inpatients (IPD) (actual treatment)OthersBeds64.8940,499
Maximum inpatient capacityOthersBeds062,415

Domestic/Overseas Purchase Proportion (Overall)

Raw MaterialSource CountryValue
Medicine and medical suppliesThailand184,774,715.1
Medical EquipmentThailand9,950,942

Nature of Business — Overview

Introduction

Ratchaphruek Hospital is located in Khon Kaen Province in Northeastern Thailand. Established in 1994 as a private general hospital with 50 beds, it has since grown into a "Healing Environment Hospital" with 198 beds by 2018.

Our vision is to provide high-quality medical services that meet international standards, with a human touch. We see our patients as patients, not customers, as we are not merchants. Similarly, we view our doctors as healthcare providers, not as service sellers. Every staff member is a "giver" of care, united by a common goal that aligns with our core organizational value: "Happiness from Giving." Stability, a critical factor for sustainable growth, stems from strength and flexibility. This strength is rooted in academic excellence, comprising four key areas: quality care, safety, positive patient experiences, and human-centered care. As a private hospital,

We must balance profitability with purpose, preserving the essence of our hospital's mission and the spirit of the medical profession. This involves achieving reasonable profits, not maximizing them at all costs.We are a hospital that fosters a healing environment, offers fair pricing to the community, and maintains international standards in medical treatment and human-centered care.

Product Information — Overview

Introduction

Initially, Ratchaphruek Hospital Public Company Limited operated as a private hospital providing secondary care (low-complexity care), offering diagnostic and treatment services as well as consultations to patients within Khon Kaen Province. Adhering to the motto “Warm as Home, Care by Expertise, Remedy by Heart”

Projects Under Construction

Has Projects Under Construction (Y/N)

No

Introduction

In 2025, the Company has no work that has not yet been delivered.

Debentures & Bills of Exchange

Has Debentures (Y/N)

No

Convertible Securities

Has Convertible Securities (Y/N)

No

Contents